WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406443
CAS#: 794466-17-4
Description: DAP-81 is a diaminopyrimidine derivative that targets PLKs, destabilizing kinetochore microtubules. Other spindle tubules are stabilized, resulting in monopolar mitotic spindles. In vitro, DAP-81 inhibits Plk1 at an IC50 of 0.9 nM. DAP-81 is currently in ongoing preclinical evaluations.
MedKoo Cat#: 406443
Name: DAP-81
CAS#: 794466-17-4
Chemical Formula: C25H20N6O4
Exact Mass: 468.1546
Molecular Weight: 468.4641
Elemental Analysis: C, 64.10; H, 4.30; N, 17.94; O, 13.66
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: DAP81; DAP 81; DAP-81.
IUPAC/Chemical Name: N-(4-((4-((2-benzoylphenyl)amino)-5-nitropyrimidin-2-yl)amino)phenyl)acetamide.
InChi Key: LOMJSEHTDFISSP-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H20N6O4/c1-16(32)27-18-11-13-19(14-12-18)28-25-26-15-22(31(34)35)24(30-25)29-21-10-6-5-9-20(21)23(33)17-7-3-2-4-8-17/h2-15H,1H3,(H,27,32)(H2,26,28,29,30)
SMILES Code: CC(NC1=CC=C(NC2=NC=C([N+]([O-])=O)C(NC3=CC=CC=C3C(C4=CC=CC=C4)=O)=N2)C=C1)=O
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 468.4641 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. doi: 10.1634/theoncologist.2009-0010. Epub 2009 May 27. Review. PubMed PMID: 19474163.
